<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; financial</title>
	<atom:link href="http://www.tapanray.in/tag/financial/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why And How To Be In-Sync With Gen Z As Pharma Paradigm Shifts?</title>
		<link>http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts</link>
		<comments>http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/#comments</comments>
		<pubDate>Mon, 21 Feb 2022 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[characteristics]]></category>
		<category><![CDATA[conscious]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Gen Z]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[Millenials]]></category>
		<category><![CDATA[minded]]></category>
		<category><![CDATA[natives]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10656</guid>
		<description><![CDATA[As science and technology, across the world, are progressing at a scorching pace &#8211; Covid-19 pandemic notwithstanding, today’s generations are growing up tech savvy &#8211; more than ever before. The trend will keep going north faster and with a steeper &#8230; <a href="http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid-19: Perils Of Haste In Scientific Decision-Making Process</title>
		<link>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-19-perils-of-haste-in-scientific-decision-making-process</link>
		<comments>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/#comments</comments>
		<pubDate>Mon, 31 Aug 2020 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[blood]]></category>
		<category><![CDATA[Chlioroquine]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[haste]]></category>
		<category><![CDATA[hydroxychloroquine]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[perils]]></category>
		<category><![CDATA[plasma]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scientific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[WIP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10243</guid>
		<description><![CDATA[Multifaceted threats posed by Coronavirus to the humanity, are getting increasingly complex, every day. Currently, Covid-19 cases in India are ‘the highest that any country has ever recorded on a single day since the start of the outbreak.’ Alongside, the hopes of billions &#8230; <a href="http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-19-perils-of-haste-in-scientific-decision-making-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Pays More: Creating ‘Innovative ‘Customer Experience’ Or ‘Innovative Drugs’?</title>
		<link>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-pays-more-creating-innovative-customer-experience-or-innovative-drugs</link>
		<comments>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/#comments</comments>
		<pubDate>Mon, 13 Jan 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[business corporate]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[dimension]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[equation]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-cycle]]></category>
		<category><![CDATA[loyal]]></category>
		<category><![CDATA[loyalty]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pays]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[prodrugs]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[word-of-mouth]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9851</guid>
		<description><![CDATA[More innovative a drug is, the better is its business success rate. This was the general perception of around 92 percent pharma professionals in the past three years. Whereas the fact is: ‘Having the best product doesn’t guarantee sales anymore’. &#8230; <a href="http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Patient Compliance To Boost Pharma Sales…And More…</title>
		<link>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-patient-compliance-to-boost-pharma-salesand-more</link>
		<comments>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/#comments</comments>
		<pubDate>Mon, 20 May 2019 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[apps]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[drug companies]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[new products]]></category>
		<category><![CDATA[non-adherence]]></category>
		<category><![CDATA[noncompliance]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[patient-compliance]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9534</guid>
		<description><![CDATA[One high-impact area in the healthcare space that often finds its place in the backseat is &#8211; patient noncompliance. A term that is commonly used in regard to ‘a patient who does not take a prescribed medication or follow a prescribed course &#8230; <a href="http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-patient-compliance-to-boost-pharma-salesand-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will AB-NHPM Mitigate Indian Healthcare Crisis?</title>
		<link>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-ab-nhpm-mitigate-indian-healthcare-crisis</link>
		<comments>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/#comments</comments>
		<pubDate>Mon, 18 Jun 2018 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Ayusman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inpatient]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHFS]]></category>
		<category><![CDATA[NHM]]></category>
		<category><![CDATA[NHPM]]></category>
		<category><![CDATA[NHRM]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[outpatient]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RSBY]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tertiary]]></category>
		<category><![CDATA[transportation]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9039</guid>
		<description><![CDATA[Since long, hypes have created on several healthcare schemes in India, by the successive Governments of different political dispensation. These attracted mostly positive vibes at the time of announcements. Nevertheless, as we move on, a vast majority of Indians continues &#8230; <a href="http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-ab-nhpm-mitigate-indian-healthcare-crisis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinical Trials: Critical Need To Improve Patient Participation With Informed Consent</title>
		<link>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent</link>
		<comments>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/#comments</comments>
		<pubDate>Mon, 18 Apr 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[consent]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[II]]></category>
		<category><![CDATA[III]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[informed]]></category>
		<category><![CDATA[IV]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[naive]]></category>
		<category><![CDATA[participation]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[phase I]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Trial]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7600</guid>
		<description><![CDATA[On April 13, 2016, an article in the Wall Street Journal (WSJ) titled, “Clinical Trials Need More Subjects” underscored an important point that the rate at which the clinical researchers are able to recruit and retain patients for ‘Clinical Trials &#8230; <a href="http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Indian Patent Regime Weak?</title>
		<link>http://www.tapanray.in/is-the-indian-patent-regime-weak/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-indian-patent-regime-weak</link>
		<comments>http://www.tapanray.in/is-the-indian-patent-regime-weak/#comments</comments>
		<pubDate>Tue, 04 Mar 2014 09:45:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[energy]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime weak]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[solar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5049</guid>
		<description><![CDATA[“India misuses its own IP system to boost its domestic industries,” US Senator Orrin Hatch commented while introducing the 2014 report of the Global Intellectual Property Centre (GIPC) on ‘International Intellectual Property (IP) Index’. In this report, India featured at the &#8230; <a href="http://www.tapanray.in/is-the-indian-patent-regime-weak/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-indian-patent-regime-weak/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Buying Physicians&#8217; Prescriptions in Cash or Kind: A Global (Dis)Order?</title>
		<link>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder</link>
		<comments>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/#comments</comments>
		<pubDate>Mon, 09 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[Article]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[congressional]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[educating physicians]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[Family]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globally]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[gut]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hidden]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[induce]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[investigation]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[lesser]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Council. of]]></category>
		<category><![CDATA[medications]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[much travelled]]></category>
		<category><![CDATA[Oregon]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[phenomenon]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[shun]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[wrenching]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2530</guid>
		<description><![CDATA[Recently a European business lobby reportedly raised its voice alleging pharma Multinational Corporations (MNCs) in China have been &#8216;unfairly targeted&#8217; by a string of investigations into bribery and price-fixing cases despite their generally ‘strong legal compliance’ and has suggested that China &#8230; <a href="http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/buying-physicians-prescriptions-in-cash-or-kind-a-global-disorder/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Curb Pharma Marketing Malpractices in India Who Bells the Cat?</title>
		<link>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat</link>
		<comments>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/#comments</comments>
		<pubDate>Mon, 18 Mar 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bribe]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[curb]]></category>
		<category><![CDATA[curbing]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[E&Y]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indictment]]></category>
		<category><![CDATA[inertia]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[Jyoti]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Mirdha]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[slovakia]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2050</guid>
		<description><![CDATA[Bribing doctors by the pharmaceutical companies directly or indirectly, as reported frequently by the media all over the world, including India, to prescribe their respective brand of drugs has now reached an alarming proportion, jeopardizing patients’ interest, seriously more than &#8230; <a href="http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Global financial meltdown vindicate that “Globalization is not Americanization”?</title>
		<link>http://www.tapanray.in/does-global-financial-meltdown-vindicate-that-globalization-is-not-americanization/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-global-financial-meltdown-vindicate-that-globalization-is-not-americanization</link>
		<comments>http://www.tapanray.in/does-global-financial-meltdown-vindicate-that-globalization-is-not-americanization/#comments</comments>
		<pubDate>Mon, 15 Feb 2010 01:30:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Americanization]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[globalization]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[meltdown]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[that]]></category>
		<category><![CDATA[vindicate]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=467</guid>
		<description><![CDATA[The economic might of the most powerful nation of the world, the United States of America, was humbled during the recent global financial crisis. Long term sustainability of the financial models and the policies, which the country has been practising &#8230; <a href="http://www.tapanray.in/does-global-financial-meltdown-vindicate-that-globalization-is-not-americanization/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-global-financial-meltdown-vindicate-that-globalization-is-not-americanization/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
